Trials / Terminated
TerminatedNCT00647192
EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- University Hospital, Saarland · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Eplerenone reduces atrial fibrillation (AF) recurrences within the first 8 weeks after electrical cardioversion of persistent AF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eplerenone | 50 mg per day |
| DRUG | Placebo | 50 mg per day |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2012-02-01
- Completion
- 2012-02-01
- First posted
- 2008-03-31
- Last updated
- 2012-02-10
Locations
2 sites across 2 countries: Germany, Netherlands
Source: ClinicalTrials.gov record NCT00647192. Inclusion in this directory is not an endorsement.